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Abstract
Anti-PD1 treatment has improved the survival of metastatic melanoma patients, yet it is unknown which patients benefit 
from the treatment. In this exploratory study, we aimed to understand the effects of anti-PD1 therapy on the patients’ immune 
system and discover the characteristics that would result in successful treatment. We collected peripheral blood (PB) sam-
ples from 17 immuno-oncology-naïve metastatic melanoma patients before and after 1 and 3 months of anti-PD1 therapy. 
In addition, matching tumor biopsies at the time of diagnosis were collected for tissue microarray. The complete blood 
counts, PB immunophenotype, serum cytokine profiles, and tumor-infiltrating lymphocytes were analyzed and correlated 
with the clinical data. Patients were categorized based on their disease control into responders (complete response, partial 
response, stable disease > 6 months, N = 11) and non-responders (progressive disease, stable disease ≤ 6 months, N = 6). 
During therapy, the PB natural killer T (NKT) cell frequency, expression of CD25 and CD45RO on cytotoxic natural killer 
(NK) cells, and serum CXC chemokine levels were significantly increased in responders. Furthermore, higher age together 
with age-associated characteristics from PB, lower frequency of PB-naïve  CD8+ T cells, and elevated levels of serum MCP-4 
and OPG were discovered as baseline predictors of treatment response. We therefore propose that in addition to T cells, anti-
PD1 treatment is associated with NK- and NKT-cell population dynamics, and that the age-associated characteristics from 
PB together with older age may contribute to prolonged PFS in anti-PD1-treated melanoma patients.
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SD  Stable disease
TMA  Tissue microarray
Introduction
Immunotherapies have come to stay in the treatment of 
advanced melanoma due to their improved efficacy that has 
translated into superior overall survival compared to conven-
tional therapies such as chemotherapy [1]. From the recent 
plethora of novel immune therapies, the checkpoints inhibit-
ing monoclonal antibodies, anti-PD1 and anti-CTLA4 have 
been promising in the treatment of metastatic melanoma [2, 
3], whereas many other are currently undergoing early clini-
cal trials [4]. The inhibition of the PD1 pathway reactivates 
the anti-tumor T-cell response by blocking the inhibitory 
signal induced by tumor cells [5]. However, no comprehen-
sive immunomonitoring of the patients during anti-PD1 has 
been performed. Especially, the in vivo effects of anti-PD1 
on other lymphocytes than T cells, such as natural killer 
(NK) and natural killer T (NKT) cells in cancer patients 
remain unexplored.
NK cells are key effectors in the first line immune defense 
due to their rapid response to virally infected and tumor 
cells. Ligands that bind to NK-cell-activating receptors are 
typically overexpressed in tumors, whereas in healthy cells, 
these activating ligands are not as abundant [6]. Further, 
the expression of major histocompatibility complex (MHC) 
class I may be downregulated in tumor cells, enabling 
them to evade  CD8+ T cells and become more sensitive to 
NK cells [7]. NKT cells are a group of T cells that have 
shared properties of both NK and T cells. When activated, 
NKT cells produce large amounts of cytokines, such as 
interferon-γ (IFN-γ), which adjust the activation of NK and 
T cells [8, 9].
To maintain balance in the immune system, the functions 
of T, NK and NKT cells are regulated via several mecha-
nisms, such as with the complex cytokine network, based on 
receptor–ligand interactions. In cancer, cytokines have both 
pro- and anti-tumor properties [10]. For example, chemotac-
tic cytokines, CXCL9 and CXCL10 may promote anti-tumor 
immune responses by recruiting NK and T cells into the 
tumor tissue thereby inhibiting angiogenesis. Conversely, 
CXCL16 enhances the tumor-promoting immune responses 
in macrophages [11]. In addition to soluble cytokines, the 
regulation of their corresponding cell surface receptors is 
crucial for controlling immune system activation. For exam-
ple, interleukins (IL) 12, 18 and 21 are known to induce 
NK-cell cytotoxicity once bound to receptors on the NK-cell 
surface [12].
During recent years, anti-PD1 has remarkably improved 
the survival of melanoma patients. In a phase 3 controlled 
study, anti-PD1-treated metastatic melanoma patients 
without prior treatment had significantly improved over-
all (OS) and progression-free survival (PFS) compared to 
chemotherapy-treated patients [13]. Anti-PD1 treatment was 
also proven to be more effective and less likely to cause 
severe adverse events (AEs) compared to chemotherapy in 
the treatment of advanced melanoma [14, 15]. However, it 
is yet unknown why only some patients benefit from anti-
PD1 therapy.
In this exploratory study, we investigated the effects of 
anti-PD1 therapy on the immune system of metastatic mela-
noma patients before and after 1 and 3 months of therapy. 
Our primary objective was to determine temporal changes 
occurring during PD1 inhibition in T-, NK and NKT cells, 
which all play a key role in tumor suppression and elimi-
nation [16, 17]. Next, we sought to delineate the immune 
and clinical characteristics between the patients who were 
responsive to the treatment compared to those that did not, 
to find a potential biomarker of response.
Materials and methods
Patients and samples
The study included 17 metastatic melanoma patients treated 
with anti-PD1 therapy; nivolumab (Bristol-Myers Squibb) or 
pembrolizumab (Merck) (patient characteristics in Table 1) 
at the Helsinki University Hospital Comprehensive Cancer 
Center. Samples were collected within a 2-year time frame 
from all volunteering patients who had not received any 
prior immuno-oncological (IO) therapy. None of the patients 
had prior autoimmune diseases and The Eastern Coopera-
tive Oncology Group performance status was scored either 
0 or 1. The metastasis stage was evaluated using the AJCC7 
staging manual [18], and responses were evaluated using the 
RECIST criteria [19].
Peripheral blood (PB) samples were collected at three 
time points: before initiation (pre), after 1 (1mo) and 
3 months (3mo) of anti-PD1 treatment (sampling and drug 
infusion schedule is illustrated in supplemental Fig. 1). 
Complete blood counts (CBC) were performed concurrently 
with the study samples during routine clinical tests. Nation-
ally evaluated values obtained from the HUSLAB labora-
tories were used as a reference. In addition, formalin-fixed 
paraffin-embedded (FFPE) tumor samples from primary and 
metastatic melanoma biopsies that were taken during the 
time of diagnosis before IO therapy were collected. Fur-
thermore, PB samples from ten healthy volunteers were col-
lected as controls.
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Immunophenotyping of peripheral blood
The lymphocyte subpopulations were immunophenotyped 
from fresh PB samples for various cell surface markers, 
including immune checkpoint receptors, markers for chem-
otaxis, cytotoxicity, and migration. The panel is presented 
in supplemental Table 1. 50,000  CD45+ lymphocytes were 
acquired with FACS Verse (BD) and the data were analyzed 
with FlowJo (FlowJo 10.4, FlowJo, LLC 2006–2017).
Serum protein analysis
Serum samples separated from fresh PB using centrifugation 
were stored in − 70 °C. The samples were analyzed with a 
proximity extension assay (Proseek Multiplex Inflammation 
panel, Olink Bioscience). The samples were run on two sep-
arate plates and duplicate samples were used to normalize 
the differences between the two runs. Protein levels were 
expressed as Normalized Protein eXpression (NPX) values, 
an arbitrary  log2-scale unit.
Tissue microarray (TMA) and multiplexed 
immunohistochemistry (mIHC)
FFPE metastatic melanoma tumor biopsies at the time of 
diagnosis, within 3 months to 1 year before initiation of anti-
PD1 therapy (n = 9, six from responders, three from non-
responders), were used. Tissue core punches 2 mm in diam-
eter were collected from the area containing cancerous cells 
to construct the TMA block. Sections from the TMA block 
were used for mIHC to stain the tumor-infiltrating lympho-
cytes (TILs) as used previously [20]. The panel included 
markers for CD3, CD4, CD8, CD25, CD56, GranzymeB, 
LAG3 and PD1.
Statistical analysis and data visualization
Statistical analysis and visualization were done with RStu-
dio (Version 1.1.383) and GraphPad Prism (Version 8.0.1 
(145)). Mann–Whitney U test was used to compare the ranks 
between the responders (R) and non-responders (NR) (two-
tailed, unpaired) and Student’s t test to examine the signifi-
cance between paired observations at different time points 
(before initiation of anti-PD1 vs. after 1 or 3 months of ther-
apy). When comparing more than two groups, Kruskal–Wal-
lis and Dunn’s multiple comparison tests were used. Due to 
the limited number of patients, no correction for multiple 
testing was performed. The range of P values are labeled 
with asterisks (*P < 0.05, **P < 0.01, ***P < 0.001).
Results
Patients’ characteristics
Our cohort consisted of 17 IO-naïve metastatic melanoma 
patients treated with anti-PD1 monotherapy. The patients 
were divided based on their treatment response as respond-
ers [R, complete response (CR, n = 2), partial response (PR, 
n = 5) or stable disease (SD, n = 4) > 6 months] and non-
responders [NR, SD ≤ 6 months, n = 1, or progressive dis-
ease (PD, n = 5)]. The median age of the responders was 71 
and non-responders 62.5 years (p = 0.04). All characteristics 
of the responder and non-responder cohorts are summarized 
in Table 1.
Patients were randomly selected for treatment with 
nivolumab (n = 7) or pembrolizumab (n = 10). Overall, 64% 
of the responders and 50% of the non-responders received 
Table 1  Patient characteristics
M1a metastasis in distant skin sites or areas under the skin or in dis-
tant lymph nodes with normal LDH, M1b metastasis in lung with 
normal LDH levels, M1c metastasis in internal organ or any other 
metastasis with elevated LDH. Best achieved response during anti-
PD1 therapy: CR complete response, PR partial response, SD stable 





 Median 71.0 (66–84) 62.5 (53–78)
Sex
 Female 5 (45%) 2 (33%)
 Male 6 (55%) 4 (67%)
Metastasis
 M1a 4 (36%) –
 M1b 3 (27%) 1 (17%)
 M1c 4 (36%) 5 (83%)
BRAFV600
 Mutated 1 (17%) 3 (50%)
 No mutation 10 (83%) 3 (50%)
PreLDH
 Median 240.0 Ul (159–357) 226.5 Ul (180–411)
Drug
 Nivolumab 4 (36%) 3 (50%)
 Pembrolizumab 7 (64%) 3 (50%)
Follow-up time
 Median 21.0 months (12–27) 21.0 months (12–27)
PFS
 Median 12.0 months (3–20) 3.0 months (1–6)
Best response
 CR 2 (18%) –
 PR 5 (45%) –
 SD 4 (36%) 1 (17%)
 PD – 5 (83%)
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pembrolizumab. All patients were monitored for follow-up at 
least 12 months from the initiation of therapy with a median 
of 21 months. The median PFS of the responders and non-
responders was 12.0 and 3.0 months, respectively.
Patients responding to PD1 inhibition have 
higher quantities of circulating lymphocytes 
during treatment
To first assess the treatment effects on the leukocyte subpop-
ulations, the frequencies and absolute values of the CBCs 
were analyzed before and during therapy.
The absolute lymphocyte count was significantly higher 
in the responders (Rmean: 1.9  109/L vs.  NRmean: 1.2  109/L, 
p = 0.04) after 3 months of anti-PD1 treatment (Fig. 1a). 
The number and proportion of the lymphocytes seemed to 
decrease in all patients, but particularly in the NR group 
during therapy. No statistically significant differences were 
observed in other leukocyte populations, except for a trend 
in lower neutrophil frequencies in the responders after 
3 months of anti-PD1 therapy compared to non-respond-
ers (Rmean 53.5% vs.  NRmean 70.0%, p = 0.06) (Fig. 1b). 
In addition, the eosinophil frequencies in a proportion 
of the responders was higher than the normal reference 
range (Rmean 8.8%, normal reference range 1.0–6.0%) after 
Fig. 1  Patients responding to 
PD1 inhibition have higher 
peripheral blood lymphocytes 
during treatment. Frequency 
and absolute count of a 
lymphocytes, b neutrophils, c 
eosinophils and d monocytes 
from peripheral blood samples 
of anti-PD1-treated metastatic 
melanoma patients before and 
during treatment. Gray areas 
indicate the normal reference 
range (Helsinki University Hos-
pital HUSLAB laboratories), 
green circles represent complete 
responders (CR), black circles 
represent responders (R), and 
black triangles represent non-
responders (NR). The statistical 
difference between R and NR 
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3 months of anti-PD1 therapy (Fig. 1c). No significant differ-
ences were observed in the monocyte populations (Fig. 1d). 
The neutrophil (NLR), eosinophil (ELR) and monocyte 
(MLR) to lymphocyte ratios did not indicate statistically sig-
nificant differences between responders and non-responders.
The responders have high frequency of PB NKT cells 
before initiation and during anti‑PD1 treatment
To study the effects of anti-PD1 treatment on the lympho-
cytes, fresh PB samples were immunophenotyped before and 
during therapy. A representative example including the gat-
ing strategy is presented in Fig. 2.
After 1 month of anti-PD1 therapy, the mean propor-
tion of the total NKT cells (R: pre 11.9% vs. 1mo 13.2%, 
p = 0.01) and  CD3bright NKT cells (R: pre 2.4% vs 1mo 3.3%, 
p = 0.007) increased in the responders, but not in the non-
responders. The mean proportion of the responders’ NKT 
 CD3bright T cells later decreased back to the pretreatment 
levels after 3 months of anti-PD1 therapy (3.3% vs. 2.2%, 
p = 0.02). Two patients who achieved complete response had 




Fig. 2  The proportion of NKT cells increases in responders after 
1  month of anti-PD1 treatment. Gating strategies of a  CD3+CD56+ 
and  CD3brightCD56+ NKT cells from lymphocytes, b  CD3+CD4+ 
and  CD3+CD8+ T cells from total T cells, c CD56dim and 
CD56bright NK cells from the total lymphocyte population before 
treatment (pre), at 1  month (1mo) and at 3  months (3mo) of anti-
PD1 therapy. Green circles represent the complete responders (CR), 
black circles represent responders (R) and black triangles represent 
non-responders (NR). The statistical difference between time points 
within same cohort was calculated with Students t test
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therapy  (CRmean vs. other Rmean; Pre: 24.5% vs. 9.1%, 1mo: 
25.0% vs. 10.6%, 3mo: 23.0% vs. 10.8%, Fig. 2a). Though 
not significant, the responders displayed a trend in higher 
mean proportions of PB NKT cells (Rmean 11.2% vs.  NRmean 
4.3%, p = 0.07) after 1 month of anti-PD1 treatment, com-
pared to non-responders. No significant changes in T- or 
NK-cell subsets in the responders and non-responders were 
observed during anti-PD1 therapy (Fig. 2b, c).
Responders’ T‑ and NK‑cell immunophenotype 
differs from non‑responders and healthy already 
before anti‑PD1 therapy
To investigate the immune checkpoint profiles on lym-
phocytes, we compared the proportion of PD1+, ICOS+, 
LAG3+ and CTLA4+ expressions on the immune cells 
(Euclidean distance). The expression of immune check-
point markers on the healthy controls’ and patients’ immune 
cells before initiation of anti-PD1 therapy is illustrated in 
the heatmap (Fig. 3a). The expression of PD1 and ICOS 
on T and NKT cells was more abundant compared to other 




Fig. 3  Pretreatment expression of immune checkpoint markers on 
T, NKT and NK cells. a Heatmap of checkpoint marker expression 
on healthy and patient T, NKT and NK cells before initiation of 
anti-PD1 therapy, clustering done using Euclidean distance. Annota-
tion bar indicating cohorts; black for non-responders (NR), pink for 
responders (R) and gray for healthy. b PD1 and c ICOS expression 
on  CD3+CD8+ and  CD3+CD8− T cells, NK cells and NKT cells at 
pretreatment stratified by response to anti-PD1 treatment and healthy 
controls. d CD25 and e CD45RO expression visualized with a den-
sity histogram and with dot plot grouped by treatment response and 
time point. Green circles represent the complete responders (CR), 
black circles represent responders (R), black triangles represent non-
responders (NR), diamonds represent healthy controls (healthy). p 
values in b and c were calculated with Kruskal–Wallis ANOVA; the 
range of p values from Dunn’s multiple comparisons test are labeled 
with asterisks. The statistical difference between time points within 
the same cohorts (d, e) was calculated with the Students t test
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were scarcely or not at all expressed in both the patient and 
healthy immune cells. No distinct clustering was observed 
between the cohorts, but PD1 and ICOS appeared to be 
more frequently expressed on the patients’ lymphocytes 
than in the healthy (Fig. 3a). Further, the expression of PD1 
was significantly higher on the responders’  CD8−CD3+ T 
and  CD56dim NK cells than in the healthy controls (mean: 
 CD8−CD3+ 55.6% vs. 34.2%, p = 0.01,  CD56dim NK: 10.7% 
vs. 3.1%, p = 0.007, respectively) (Fig. 3b). In contrast, the 
pretreatment ICOS expression was significantly higher in the 
non-responders’  CD8+CD3+ T,  CD8−CD3+ T, and  CD56dim 
NK cells, as well as the responders’  CD56dim NK cells when 
compared to the healthy controls (mean:  CD8+CD3+ 54.4% 
vs. 20.9%, p = 0.03,  CD8−CD3+ 67.4% vs. 41.5%, p = 0.02, 
NR  CD56dim NK 16.9% vs. 1.7%, p = 0.01, R  CD56dim NK 
12.8% vs. 1.7%, p = 0.002, respectively) (Fig. 3c).
The NK-cell phenotyping indicated that the receptors 
CD45RO and CD25 were more frequently expressed in a 
proportion of the responders’  CD56dim NK cells, but no sig-
nificant differences between responders and non-responders 
were observed. However, the expression of both markers 
on the responders’  CD56dim NK cells was significantly 
increased after 1 month of therapy (CD25: pre 23.0% vs. 
1mo 28.6%, p = 0.03, CD45RO: pre 21.1% vs. 1mo 27.6%, 
p = 0.04), and after 3 months, the CD25 expression moder-
ately decreased toward pretreatment levels (1mo 28.6% vs. 
3mo 25.1%, p = 0.04) (Fig. 3d, e).
Anti‑PD1 therapy increases plasma CXCR3 ligands 
and lymphocyte‑activating chemokines in the blood
To further study the effects of anti-PD1 therapy on the 
immune system, we performed a proximity extension assay 
to detect 92 different serum proteins before and during ther-
apy. In addition, sera from ten healthy donors were analyzed 
as reference controls.
The results indicated that the levels of the chemokine 
ligands, CXCL9, CXCL10 and CXCL11, binding to the CXC 
family chemokine receptor (CXCR3), were significantly 
increased in the patients after 1 month of anti-PD1 ther-
apy (NPX values CXCL9: pre 390 vs. 1mo 901, p < 0.001, 
CXCL10: pre 1000 vs. 1mo 2080, p = 0.03, CXCL11: pre 45 
vs. 1mo 71, p = 0.01, pre 45 vs. 3mo 56, p = 0.05; Fig. 4a). 
Further analysis of these chemokine ligand levels indicated 
that the increase occurred mainly in the responders after 
1 month of anti-PD1 therapy (NPX CXCL9: pre 430 vs. 1mo 
1010, p = 0.001, CXCL10: pre 1300 vs. 1mo 2600, p = 0.03, 
CXCL11: pre 50 vs. 1mo 78, p = 0.03). However, no changes 
were observed in the non-responders (Fig. 4b).
As the CXC family ligands were known to bind to the 
CXCR3 receptor and induce lymphocyte tumor infiltration 
[21–23], we next correlated the CXC ligand serum levels 
and expression of the CXCR3 receptor in T cells before the 
initiation of therapy. The phenotype of the PB lymphocytes 
indicated that the expression of CXCR3 was most frequently 
expressed in the responders’  CD8−CD3+ T cells before ini-
tiation of therapy when compared to the non-responders and 
healthy controls (R: 71% vs. NR: 49% vs. H: 37%, NR vs. H, 
p = 0.001) (Fig. 4c). Our results indicated a positive correla-
tion between the pretreatment CXCL9 and CXCR3 expres-
sion levels (r = 0.58, p = 0.02), and a trend between CXCR3 
and CXCL10/11 (Fig. 4d).
The Olink assay also indicated heightened levels of other 
immune cell-stimulating cytokines in the responders’ serum 
after initiation of anti-PD1 therapy; NK-cell stimulatory fac-
tor 2 (IL-12B: pre 34 vs 1mo 46, p = 0.01, pre 34 vs. 3mo 42, 
p = 0.009) and tumor necrosis factor receptor superfamily 
member 9 (TNFRSF9: pre 130 vs. 1mo 170, p = 0.03, pre 
130 vs. 3mo 160, p = 0.02). Moreover, after 3 months of 
therapy, the responders had higher levels of IL-12B in their 
sera compared to the non-responders (42 vs. 20, p = 0.02, 
respectively) (Fig.  4e, f). No significant changes were 
observed in the non-responder serum samples. All serum 
protein levels at the three studied time points are shown in 
the supplemental Fig. 2.
Responders’ tumor harbor granzyme B‑expressing 
 CD4+CD3+T cells
From the findings in the serum protein levels, we sought 
to further investigate the intratumoral lymphocytes with 
mIHC. Two representative cases, one responder and non-
responder, are shown in supplemental Fig. 3. From the tumor 
biopsy taken from a well-responding patient, we found a 
number of  CD4+ T cells secreting granzyme B (GrB), but 
little to none were found in the biopsy obtained from the 
non-responder. However, no statistically significant differ-
ences were observed between the biopsy phenotypes of the 
responders and non-responders.
Age‑associated characteristics may contribute 
to enhanced therapy response to PD1 inhibition
To find potential biomarkers of response, we further ana-
lyzed the differences between responding and non-respond-
ing patients before initiation of anti-PD1 therapy.
The average-weighted absolute difference in median 
values at pretreatment between the responder and non-
responder groups using the Mann–Whitney U test indi-
cated that the responders had significantly higher levels 
of serum MCP-4, OPG, IL-10RB, IL-15RA, HGF [differ-
ence in median (d): d = 0.52, p = 0.01; d = 0.42, p = 0.02; 
d = 0.27, p = 0.02; d = 0.11, p = 0.03; d = 0.35, p = 0.03, 
respectively), and a higher proportion of PB PD1-express-
ing  CD56bright NK cells (d = 0.55, p = 0.03). In addition, 
the responders were significantly older (d = 0.13, p = 0.05) 
724 Cancer Immunology, Immunotherapy (2020) 69:717–730
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than the non-responders and had a significantly lower pre-
treatment proportion of NKp30-expressing  CD3bright NKT 
cells (d = − 1.70, p = 0.02), NKG2C and CD25-expressing 
 CD8+ T cells (d = − 0.66, p = 0.02, d = − 1.24, p = 0.02, 
respectively) and naïve  CD8+ T cells (d = − 0.44, p = 0.03) 
(Fig. 5a).
A correlation analysis was used to further deter-





Fig. 4  Cytokines related to antitumor immune response increase in 
responders’ peripheral blood during anti-PD1 treatment. Cytokine 
levels of CXCL9, CXCL10 and CXCL11 in a all patients at differ-
ent time points and b in responders (R) vs. non-responders (NR) 
measured with the Olink immunoassay. c Proportion of  CXCR3+ 
 CD3+CD8− T cells at pretreatment defined by flow cytometry in R, 
NR and healthy subjects. d Correlation of  CXCR3+  CD3+CD8− T 
cells and serum CXCL9, CXCL10 and CXCL11. e Cytokine levels 
of IL-12B and f TNFRSF9 in R and NR. Protein levels are presented 
as Normalized Protein eXpression (NPX) values, an arbitrary unit on 
the  log2-scale. Green circles represent the complete responders (CR), 
black circles represent responders (R) and black triangles represent 
non-responders (NR), diamonds represent healthy controls (healthy). 
Statistical differences between time points within the same cohort 
were calculated with the Student’s t test (a, b, e, f), and the range 
of the p values are labeled with asterisks. Statistical differences in c 
were calculated with Kruskal–Wallis test (p values) and Dunn’s mul-
tiple comparisons test (asterisks). Statistical differences between the 
two cohorts, R vs NR, in e were calculated using the Mann–Whitney 
U test. Correlation analysis was done using Spearman’s correlation
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analysis indicated that patient age significantly correlated 
with the proportion of  CD8+-naïve T cells, NKp30-express-
ing  CD3bright NKT cells and serum OPG, IL-15RA and 
MCP-4 levels (Spearman correlation: r = − 0.61, p = 0.01; 
r = − 0.56, p = 0.04; r = 0.54, p = 0.04; r = 0.6, p = 0.01; 




Fig. 5  Age-associated factors before initiation of therapy are related 
to prolonged progression-free survival. a Average-weighted absolute 
difference in median values between responders (R) and non-respond-
ers (NR) cohorts at pretreatment visualized in volcano plot, p values 
presented as − log10 scale and a p value of 0.05 was set as a thresh-
old for variable labeling, variables 0 < represent higher median in R. 
b Correlation of the significantly different variables between R and 
NR at pretreatment. Correlation calculated using spearman correla-
tion and p value of 0.05 was set as a threshold for variables shown in 
the plot. The association of these significant variables with PFS was 
studied using Cox regression analyses and visualized using Kaplan–
Meier curves. Patients were grouped into two cohorts as higher or 
equal (≥) and lower (<) the median c age, d  CD3+CD8+-naïve T 
cells, e OPG or f MCP4 at pretreatment
726 Cancer Immunology, Immunotherapy (2020) 69:717–730
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Furthermore, we studied the age- and treatment response-
associated parameters with PFS using Cox regression analy-
sis, by grouping patients into two cohorts as higher or equal 
(≥) and lower (<) median of each parameter. The analysis 
indicated that patients who were 70 years or older at the time 
of initiation of anti-PD1 had significantly longer PFS (HR 
0.36 95% CI 0.1–1.3, p = 0.03) (Fig. 5c). The lower propor-
tion (< 12% of  CD8+ T cells) of PB-naïve  CD8+ T cells 
before therapy initiation also significantly correlated with 
longer PFS (HR 0.36, 95% CI 0.1–1.2, p = 0.04) (Fig. 5d). In 
addition, high pretreatment levels of serum OPG and MCP-4 
significantly correlated with longer PFS (HR 0.28, 95% CI 
0.1–1.0, p = 0.008) (Fig. 5e, f).
Discussion
Novel immune checkpoint inhibitors, such as anti-PD1, have 
shown great promise in treating solid tumors, especially in 
metastatic melanoma [13–15]. However, the overall effects 
of the treatment on the immune system are poorly under-
stood. A deeper understanding of these effects could poten-
tially aid in the discovery of biomarkers and improve patient 
selection for the treatments. In this study, we hypothesized 
that NK, NKT and T cells are influenced by PD1 inhibition 
in metastatic melanoma patients, and that the therapy would 
potentially affect the immunophenotype. Moreover, we were 
interested in the pretreatment differences in the PB lympho-
cytes and plasma protein profiles between the responders 
and non-responders to identify novel biomarkers of response 
to anti-PD1 therapy.
Besides T cells, NK and NKT cells are known to have 
diverse functions in antitumor immune responses by directly 
killing malignant cells or induce cells such as  CD8+ T cells 
to attack the tumor via the immune-activated production 
of cytokines [16, 24]. Anti-PD1 monoclonal antibodies 
are designed to inhibit the inactivating binding of the pro-
grammed death-ligand 1 (PD-L1), by binding to the PD-1 
receptor on the surface of an activated T cell, thus enabling 
the antitumor immune response by T cells [5]. PD1 expres-
sion on NK cells has been previously described in cancer 
patients and human cytomegalovirus (HCMV) seropositive 
healthy individuals, and similarly to  CD8+ T cells, high 
PD1 expression on NK cells has been characterized as a 
sign of exhaustion, with lower degranulation or cytotoxic 
activity and cytokine production compared to  PD1neg NK 
cells [25–28]. Our results were in line with the previous 
observations that besides PB T cells, PB NK and NKT cells 
also express PD1 receptors on their surface, supporting our 
hypothesis that these cells may play an important role in 
the anti-PD1-mediated antitumor effect for metastatic mel-
anoma patients. The contribution of the PD1 blockade to 
NK- and NKT-mediated anti-tumor immune responses have 
previously been shown in murine models [29, 30]; however, 
no clear evidence of the effects in humans have previously 
been described.
In this study, we observed that the expressions of CD25 
and CD45RO increased in the responders’ cytotoxic 
 CD56dim NK cells after 1 month of anti-PD1 therapy. Pre-
vious studies have shown that the expression of CD25 and 
CD45RO on NK cells have indicated an effector-like phe-
notype that has been associated with enhanced prolifera-
tion, active degranulation and NK-cell-mediated cytotoxicity 
[31–33]. The  CD45RO+ NK cells have especially been iden-
tified with antitumor activity in hematological cancers [33, 
34]; thus, we believe that anti-PD1 therapy could directly or 
indirectly enhance the cytotoxic potential of NK cells in the 
responders. Although not significant, we observed that the 
mean levels of both markers were higher in the responders 
before treatment, compared to non-responders, suggesting 
that the responders’ NK cells may already possess a more 
activated phenotype that is further enhanced with anti-PD1 
treatment.
Moreover, we noticed that during anti-PD1 therapy, a pro-
portion of the PB NKT cells increased in responders, and 
the highest NKT-cell percentage was observed in patients 
with a complete response to anti-PD1. Interestingly, these 
complete responders clearly possessed the highest NKT-cell 
proportion already before initiation of treatment. The mean 
PB NKT-cell reference value is 5.5% out of the total  CD3+ 
[35], and the number of circulating type I NKT cells (invari-
ant NKT cells) have been reported to decrease in different 
malignancies compared to healthy controls [24]. In addi-
tion, Ibarrondo et al. have shown that melanoma patients 
responding to anti-CTLA4 treatment have high frequencies 
of circulating NKT cells before and after treatment [36]. 
Hence, we believe that the high frequency of circulating 
NKT cells could provide a clinical advantage to melanoma 
patients treated with anti-PD1, and that the treatment may as 
well influence the NKT-frequency. However, further studies 
are needed to determine the exact role of these NKT cells to 
be utilized as a predictive marker for response.
One potential mechanism of anti-PD1-mediated lym-
phocyte modulation is the cytokine production pathway. 
NK and NKT cells are known to produce large amounts of 
cytokines such as IFNγ, which may further induce the acti-
vation of other lymphocytes. Interestingly, we found that 
the IFNγ-inducible chemokines, CXCL9-11, were signifi-
cantly increased in the responders after the first month of 
anti-PD1 therapy. Similarly, Chow et al. recently reported 
an increase of CXCL9 and CXCL10 in melanoma patients 
who responded to anti-PD1 therapy. Further, the in vivo 
Cxcr3−/− model indicated that the efficacy of anti-PD1-
mediated tumor control is dependent on the intratumoral 
CXCR3 receptor–ligand interaction [37]. The CXCL9-11 
chemokines are known to bind CXCR3 and are involved 
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highest expression of CXCR3 on the  CD4+ T cells as well 
as CXCL9 serum levels.
Subsequently, the observed immunological changes 
during anti-PD1 therapy mainly occurred in the respond-
ers, but not in the non-responders. Moreover, the complete 
Fig. 6  Putative role of observed immunological changes in respond-
ers and non-responders. (1) The frequency of PB NKT cells is higher 
and naïve T cells lower in the responders after initiation of anti-PD1 
treatment. (2) NKT cells are able to produce large quantities of IFNγ, 
a known activator of other lymphocytes, such as cytotoxic NK- and T 
cells. IFNγ has also been previously shown to induce the production 
of CXCL9, -10, and -11 chemokines in tumor microenvironment. (3) 
CXCL9, -10, and -11 are known to induce T-cell migration and infil-
tration into tumor via CXCR3 interaction. Anti-PD1 treatment blocks 
the inactivating binding of PD-L1 to its receptor on the surface of 
cytotoxic T-cell enabling the antitumor immune response. (4) CXCR3 
ligands (CXCL9, -10, and -11) could be released into circulation as 
a result of tumor cell lysis, which may further enhance the loop by 
(5) attracting lymphocytes to the tumor site. Further, the responders 
have increased levels of serum OPG and MCP4, which are cytokines 
associated with age; however, their role in positive response to anti-
PD1 requires further studies. (6) Non-responders have less circulat-
ing NKT cells, thus the production of IFNγ may be insufficient in 
activating other lymphocytes and inducing the production of CXCR3 
ligands in the tumor microenvironment. (7) Without chemokine 
attraction, the cytotoxic T cells may not be able to migrate to the 
tumor site, leading to (8) insufficient antitumor immune response, 
tumor growth and disease progression
in inducing the infiltration of T and NK cells into the 
tumor as well as tumor suppression [21–23]. Our results 
also indicated that high CXCR3 expression on the  CD4+ T 
cells correlated with high CXCL9 levels before the initia-
tion of anti-PD1 therapy, and moreover, responders had the 
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responders often harbored distinct immunological profiles 
with regards to these variables even before the initiation 
of therapy. Henceforth, we were interested to find out the 
pretreatment characteristics that were different between 
the responders and non-responders. Our results indicated 
that the responders had distinct cytokine profiles from non-
responders, notably MCP-4, OPG, IL-10RB and HGF, 
which were significantly more abundant in the responders’ 
sera compared to non-responders. Further, the responders 
had lower proportions of PB-naïve  CD8+ T cells and were 
older in age. Because a decline in the quantity of naïve  CD8+ 
T cells is considered as a hallmark of the aging immune sys-
tem [38], we wanted to study whether the elevated cytokine 
levels would be associated with age. Interestingly, our results 
indicated significant correlation of old age with a low pro-
portion of naïve  CD8+ T cells and elevated levels of OPG 
and MCP4. In addition to our findings, a previous study by 
Larsson et al. indicated the association of age with elevated 
levels of certain serum cytokines, including MCP-4, OPG, 
IL-10RB and HGF [39].
Aging is an intricate process of gradual deterioration that 
significantly affects the immune system. Immunosenescence 
refers to the deterioration of the immune system with aging, 
affecting the capacity to generate specific immune responses 
and long-term immune memory. Due to immunosenescence, 
older patients would in theory, benefit less from immuno-
logical therapies [40]. However, emerging evidence sug-
gests that older age might contribute to clinical benefits 
for patients treated with immune checkpoint inhibitors [41, 
42]. The association of age with improved response to anti-
PD1 therapy has recently been observed in a large cohort of 
Danish metastatic melanoma patients; patients between ages 
70–80 years had significantly longer OS and PFS compared 
with younger patients [43]. Furthermore, Perier-Muzet et al. 
indicated that old age may improve the anti-PD1 response 
without increasing the risk for severe adverse events [44]. 
In addition, Kuegel et al. described the positive association 
between age and anti-PD1 response in melanoma patients, 
and demonstrated that the tumor microenvironment in older 
subjects is more favorable for anti-PD1-mediated antitumor 
response in murine models [45]. Similarly, the correlation of 
clinical benefit and older age, yet together with multiple age-
associated biological variables, was seen in our small cohort 
of metastatic melanoma patients. Our results indicate that a 
low frequency of naïve  CD8+ T cells, and elevated levels of 
OPG and MCP4 have strong statistical association to older 
age and prolonged PFS.
The comprehensive mechanism of action of the antitumor 
effect, with the exception of the reactivation of cytotoxic 
 CD8+ T cells, in the PD1 blockade is not fully resolved. 
Additionally, our data suggest that the anti-PD1 treat-
ment increases the frequency of PB NKT cells, the levels 
of IFNγ-inducible CXC family cytokines and potentially 
enhances the cytotoxicity of NK cells. We believe that the 
responders’ NKT cells may play a central role orchestrat-
ing the anti-PD1-mediated antitumor immune responses by 
producing cytokines that direct other lymphocytes to the site 
of action and activates the cytotoxic effect of these cells. A 
summary of our results is illustrated in Fig. 6.
As observed, we propose that the age-associated biologi-
cal characteristics in PB and the increased frequency of NKT 
cells could potentially contribute to an improved survival 
for melanoma patients treated with anti-PD1 therapy. This 
observation needs to be investigated further with larger and 
prospective clinical immunotherapy trials.
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